The combination of two beta-glucans produced by Aureobasidium Pullulans (AFO-202 and N-163) strains along with standard treatment was shown to reduce inflammatory biomarkers in COVID-19 patients, compared to just the standard treatment alone.
Content provided by Aker BioMarine | 26-Feb-2024
| White Paper
The global population is getting older—according to WHO by 2050 the world’s population over 60 years will double and the population above 80 years will...